Skip to main content

Table 5 GI symptoms and QOL comparisons between IBS-D patients with and without SIBO eradication after rifaximin treatment

From: Short-course Rifaximin therapy efficacy and lactulose hydrogen breath test in Chinese patients with diarrhea-predominant irritable bowel syndrome

Clinical factors

LHBT (+)

LHBT (−)

P value

GI symptoms (mean)

7.88 ± 6.15

8.95 ± 5.23

0.531

Abdominal discomfort

1.64 ± 1.29

1.20 ± 1.20

0.243

Abdominal distension

0.92 ± 1.04

0.90 ± 1.29

0.956

Abdominal pain

1.64 ± 1.35

1.45 ± 1.28

0.631

Defecatory urgency

1.32 ± 1.44

2.05 ± 1.28

0.078

Diarrhea

1.20 ± 1.29

1.95 ± 1.10

0.051

Incomplete evacuation

1.16 ± 1.11

1.55 ± 1.15

0.256

Quality of life (mean)

579.93 ± 106.11

599.05 ± 88.29

0.513

Physical Functioning

96.20 ± 4.63

98.25 ± 3.73

0.107

Role-physical

70.00 ± 35.36

81.25 ± 25.49

0.222

Bodily pain

71.92 ± 14.29

73.68 ± 15.41

0.697

General Health

53.60 ± 19.72

53.85 ± 16.69

0.963

Vitality

63.80 ± 14.74

64.00 ± 15.01

0.965

Social Functioning

84.57 ± 12.92

82.95 ± 13.41

0.685

Role-Emotional

72.00 ± 32.89

81.67 ± 33.29

0.336

Mental Health

67.84 ± 17.42

63.40 ± 18.55

0.417

  1. Note: IBS, irritable bowel syndrome; IBS-D, diarrhea-predominant IBS; GI symptoms, gastrointestinal symptoms; QOL, quality of life; SIBO, small intestinal bacterial overgrowth
Back to article page

BMC Gastroenterology

ISSN: 1471-230X

Contact us